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Impact of renal failure on the risk of myocardial infarction and and accounts for 45% of deaths [1]. A potential cause
death. for the increased cardiovascular mortality in dialysis pa-
Background. It is unclear whether pre-existing cardiovascu- tients is a higher prevalence of pre-existing CVD in thelar disease or predisposition of the uremic state leads to the
patient with chronic renal failure. Indeed, it has beenhigh cardiovascular morbidity and mortality associated with
suggested that the increased CVD and cardiovascularrenal failure. We examined whether renal failure indepen-
dently increases the risk of myocardial infarction and death. mortality in patients with renal failure is due to sub-
Methods. A total of 8600 patients with variable glomerular clinical coronary disease that is not evident by demo-
filtration rate (GFR) at the time of coronary angiography par- graphics and baseline conventional risk factors [2]. Theticipated in the Intermountain Heart Study. Coronary disease
reported 45% prevalence of atherosclerotic diseases atwas defined as 70% stenosis. Modification of Diet in Renal
the initiation of chronic dialysis supports this hypothesisDisease formula was used to calculate glomerular filtration
rate (GFR). Cox regression models were used to compare [3]. The incidence of cardiovascular events in the dialysis
outcomes. population, however, far exceeds that in the general pop-
Results. The mean GFR was 71  24 mL/min. There were ulation and cannot be readily explained by conventional1320 (15%) deaths, 657 (9%) myocardial infarctions and 1776
cardiovascular risk factors [4]. In addition, dialysis pa-(21%) death or myocardial infarctions over 3.2  1.9 years.
tients have a tenfold increased risk for cardiovascularCompared to the highest GFR quartile, the lowest GFR
quartile (mean GFR 41  14 mL/min) was associated with death compared to the general population, adjusted for
higher risk for myocardial infarction (RR 1.43, 95% CI 1.15 age, sex, race and diabetes [2]. This extraordinary high
to 1.78), death (RR 2.77, 95% CI 2.32 to 3.30) and death/ incidence of cardiovascular events and death suggest thatmyocardial infarction (RR 2.13, 95% CI 1.85 to 2.45) in multi-
they may not be attributed to pre-existing cardiovascularvariable models adjusted for age, sex, hypertension, hyperlipid-
burden alone.emia, smoking, family history of coronary disease and diabetes.
Even after further adjustment for coronary angiographic data An alternative potential explanation of the high inci-
and the choice of initial therapy, lowest GFR quartile was dence of cardiovascular events and mortality in this pop-
associated with increased risk of myocardial infarction (RR ulation is that uremia per se accelerates atherosclerosis.1.51, 95% CI 1.21 to 1.88), death (RR 2.60, 95% CI 2.18 to
There are no longitudinal studies on the relationship3.10) and death/myocardial infarction (RR 2.08, 95% CI 1.80
between renal function determined by glomerular filtra-to 2.39).
Conclusions. Even moderate renal failure increases the risk tion rate (GFR) and the risk of myocardial infarction
of myocardial infarction and death independent of clinical vari- (MI) and death adjusted for angiographic evidence of
ables, baseline angiographic evidence of coronary disease and coronary disease. In this study, we examined the associa-therapy.
tion of baseline GFR with subsequent risk of MI and
death, controlled for baseline angiographic data on coro-
Cardiovascular disease (CVD) is the leading cause of nary disease in 8600 patients.
death in patients undergoing maintenance hemodialysis
METHODS
Key words: uremia, cardiovascular disease, myocardial infarction, ath-
Study populationerosclerosis, death.
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procedures were previously described [5–13]. This is a 2002 by the International Society of Nephrology
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prospective registry of patients undergoing coronary an- troponin) were used to define MI. These were ascer-
tained from records of admissions to LDS or affiliatedgiography at the LDS Hospital, Salt Lake City, Utah.
The primary cardiologist of the patient determined the Intermountain Health Care Hospitals. In addition, re-
cords from other hospitals were used to verify patientindications and performed the angiography. Subjects
from the referral area are primarily of European extrac- reported admissions (on a telephone survey) to other
hospitals for cardiac events. Death was ascertained fromtion and are genetically similar to other U.S. Caucasians
[14]. Patients seen from September 1993, to December electronic death records from the State of Utah and the
Social Security death data.2000 with blood urea nitrogen (BUN) and serum creati-
nine determined within 30 days prior to angiography The highest GFR quartile was used as the reference
group. Cox regression models were used to examine thewere included in this analysis.
relative risks of MI, death and death/MI in the other
Data collection three groups. Univariable associations of GFR and other
clinical variables with each of these three outcomes wereComputerized data forms were used to capture key
clinical variables such as age, sex, diabetes mellitus, hy- examined. In addition, two levels of multivariable mod-
els that included clinical variables with or without angio-pertension, smoking, hyperlipidemia, presenting cardiac
diagnosis and family history of coronary heart disease. graphic data and the type of therapy were used to exam-
ine the association of GFR with each of these outcomes.Diabetes was defined as fasting blood sugar126 mg/dL,
glycosylated hemoglobin 7.5%, or hypoglycemic ther- These analyses were repeated with GFR as a continuous
variable.apy [8, 11]. Hypertension was defined as a history of
systolic blood pressure 160 mm Hg, diastolic blood Proportionality assumptions were tested by including
a multiplicative term of GFR and time and were notpressure90 mm Hg, or antihypertensive therapy [8, 11].
Current or past history of cigarette smoking was consid- violated. Kaplan-Meier survival plots of GFR quartiles
in relation to MI, death and death/MI were examined.ered smoking [8, 11]. Hyperlipidemia was defined as the
clinical diagnosis of hyperlipidemia noted in the medical
record or use of lipid modifying therapy [8, 11]. Family
RESULTS
history was positive if clinical coronary artery disease
A consecutive series of 8600 patients with baseline(CAD) appeared in a first-order relative before the age
data on serum creatinine and blood urea nitrogen wereof 65 years [8, 11].
identified and followed for a mean duration of 3.2  1.9The clinical presentation at index hospitalization was
years. Mean age ( SD) at baseline was 62.8  13.1categorized as stable angina (stable exertional symptoms
years. Men (68.5%) and Caucasians (86.8%) were pre-only), unstable angina (progressive symptoms or symp-
dominant. The mean ( SD) GFR of the entire cohorttoms at rest), or MI (clinical history, serial electrocardi-
was 70.9 23.5 mL/min. Stable angina (61.3%), unstableography and cardiac markers such as CK-MB and/or
angina (18.0%) and acute MI (20.7%) were the indica-troponin). The cardiologist of each patient reviewed the
tions for coronary angiography. Clinical diagnoses of dia-angiograms to determine the presence and severity of
betes (16.9%), hypertension (49.6%), smoking (20.9%),coronary disease in a format modified after the Coronary
hyperlipidemia (43.4%) and family history of coronaryArtery Surgery Study (CASS) protocol [15]. Therapeutic
disease (26.2%) were common. On angiogram, 29.7%strategies based on angiographic data were classified as
had no CAD, 29.0% had 1-vessel CAD, 19.1% hadmedical therapy, percutaneous coronary interventions
2-vessel and 22.2% had 3-vessel CAD. Medical therapy(stent/angioplasty), coronary bypass graft (CABG) and
(55.0%), percutaneous coronary interventions (31.5%),CABG after failed stent/angioplasty.
CABG (12.7%) and CABG after failed stent/angioplastySeveral formulae derived from the Modification of
(0.8%) were used. There were 657 (8.9%) subsequentDiet in Renal Disease Study were better predictors of
MI, 1320 (15.3%) deaths and 1776 (20.7%) death/MIGFR than 24-hour creatinine clearance [16]. A recent
events during the follow-up.simplified equation utilized age, sex, race, blood urea
The results of univariable and multivariable Cox re-nitrogen and serum creatinine and not serum albumin
gression models are summarized in Tables 1 to 3. Kaplan-(abstract; Levey et al, J Am Soc Nephrol 11:A0828, 2000).
Meier survival curves for the primary end point ofThis formula was used to measure the baseline GFR of
death/MI and secondary end points of MI alone andthe cohort in the current study.
death alone are represented in Figures 1 to 3. In univari-
Outcome measures and statistical methods able Cox regression, the lowest GFR quartile had 2.8-
fold increased risk of death/MI, 1.5-fold increased riskThe primary outcome of interest was a composite of
of MI and 4.2-fold higher risk of death compared todeath/MI. Secondary outcomes of interest were fatal or
the highest GFR quartile (Tables 1–3). In multivariablenon-fatal MI and all-cause death. Clinical history, serial
electrocardiography and cardiac markers (CK-MB and/or model adjusted for clinical variables, the lowest GFR
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Table 1. Association of GFR quartiles with death/MI in univariable and multivariable models
RR for death/MI (95% CI)
RR for death/MI (95% CI) adjusted for clinical,
RR for death/MI (95% CI) adjusted for clinical angiographic, and
Variable Univariable models variables treatment variables
GFR quartiles (meanSD)
86 (10013) mL/min 1.00 1.00 1.00
71–86 (784) mL/min 1.03 (0.88–1.20) 0.93 (0.80–1.090) 0.95 (0.81–1.10)
57–70 (654) mL/min 1.21 (1.04–1.41) 1.02 (0.87–1.19) 1.01 (0.87–1.18)
57 (4113) mL/min 2.78 (2.44–3.18) 2.13 (1.85–2.45) 2.08 (1.80–2.39)
Age per each decade increase 1.36 (1.30–1.41) 1.28 (1.23–1.34) 1.23 (1.18–1.29)
Men vs. women 0.90 (0.81–0.99) 1.08 (0.98–1.19) 0.99 (0.89–1.10)
Hypertension present vs. absent 1.02 (0.93–1.12) 0.92 (0.83–1.02) 0.90 (0.81–0.99)
Hyperlipidemia present vs. absent 0.80 (0.72–0.88) 0.82 (0.74–0.91) 0.76 (0.69–0.85)
Diabetes present vs. absent 1.61 (1.44–1.80) 1.63 (1.45–1.82) 1.55 (1.39–1.74)
Family history present vs. absent 0.78 (0.69–0.87) 0.90 (0.80–1.01) 0.88 (0.79–0.99)
Smoking present vs. absent 0.89 (0.79–1.00) 1.14 (1.01–1.28) 1.12 (1.0–1.27)
Number of stenotic lesions,
per lesion increase 1.09 (1.07–1.10) Not included in the model Not included in the model
Number of stenotic vessels Not included in the model
No vessels stenosed 1.00 1.00
1 vessel stenosed 1.19 (1.04–1.36) 1.39 (1.19–1.62)
2 vessels stenosed 1.34 (1.15–1.54) 1.52 (1.30–1.79)
3 vessels stenosed 2.05 (1.81–2.34) 2.14 (1.85–2.48)
Type of treatment Not included in the model
Medical therapy only 1.00 1.00
PCI 0.95 (0.86–1.05) 0.86 (0.77–0.97)
CABG 0.88 (0.76–1.01) 0.63 (0.54–0.74)
CABG (after failed PCI) 0.61 (0.33–1.13) 0.44 (0.23–0.84)
Table 2. Association of GFR quartiles with death in univariable and multivariable models
RR for death (95% CI)
RR for death (95% CI) adjusted for clinical,
RR for death (95% CI) adjusted for clinical angiographic, and
Variable Univariable models ariables treatment variables
GFR quartiles (meanSD)
86 (10013) mL/min 1.00 1.00 1.00
71–86 (784) mL/min 1.12 (0.92–1.37) 0.98 (0.80–1.19) 0.97 (0.80–1.19)
57–70 (654) mL/min 1.57 (1.30–1.90) 1.21 (1.00–1.48) 1.19 (0.98–1.44)
57 (4113) mL/min 4.12 (3.49–4.87) 2.77 (2.32–3.30) 2.60 (2.18–3.10)
Age per decade increase 1.57 (1.49–1.66) 1.45 (1.37–1.52) 1.40 (1.33–1.48)
Men vs. women 0.79 (0.70–0.88) 1.01 (0.90–1.13) 0.97 (0.86–1.09)
Hypertension present vs. absent 0.96 (0.86–1.07) 0.83 (0.74–0.94) 0.83 (0.74–0.93)
Hyperlipidemia present vs. absent 0.68 (0.61–0.77) 0.73 (0.65–0.83) 0.73 (0.64–0.82)
Diabetes present vs. absent 1.83 (1.61–2.07) 1.92 (1.69–2.18) 1.84 (1.62–2.10)
Family history present vs. absent 0.70 (0.61–0.81) 0.90 (0.79–1.04) 0.89 (0.77–1.02)
Smoking present vs. absent 0.78 (0.68–0.91) 1.14 (0.99–1.32) 1.14 (0.99–1.33)
Number of stenotic lesions,
per lesion increase 1.09 (1.07–1.11) Not included in the model Not included in the model
Number of stenotic vessels Not included in the model
No vessels stenosed 1.00 1.00
1 vessel stenosed 0.76 (0.65–0.89) 1.04 (0.87–1.24)
2 vessels stenosed 1.05 (0.89–1.24) 1.26 (1.05–1.51)
3 vessels stenosed 1.66 (1.44–1.92) 1.65 (1.41–1.95)
Type of treatment Not included in the model
Medical therapy only 1.00 1.00
PCI 0.62 (0.55–0.70) 0.64 (0.55–0.74)
CABG 0.88 (0.75–1.02) 0.68 (0.57–0.81)
CABG (after failed PCI) 0.69 (0.36–1.33) 0.52 (0.26–1.04)
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Table 3. Association of GFR quartiles with myocardial infarction in univariable and multivariable models
RR for MI (95% CI)
RR for MI (95% CI) adjusted for clinical,
RR for MI (95% CI) adjusted for angiographic, and
Variable Univariable models clinical variables treatment variables
GFR quartiles (meanSD)
86 (10013) mL/min 1.00 1.00 1.00
71–86 (784) mL/min 0.89 (0.71–1.11) 0.88 (0.71–1.09) 0.91 (0.73–1.13)
57–70 (654) mL/min 0.84 (0.67–1.05) 0.78 (0.62–0.99) 0.80 (0.63–1.02)
57 (4113) mL/min 1.53 (1.25–1.88) 1.43 (1.15–1.78) 1.51 (1.21–1.88)
Age per decade increase 1.10 (1.03–1.17) 1.08 (1.02–1.16) 0.99 (0.92–1.06)
Men vs. women 1.13 (0.95–1.33) 1.26 (1.06–1.50) 1.01 (0.85–1.21)
Hypertension present vs. absent 1.24 (1.07–1.45) 1.15 (0.98–1.37) 1.08 (0.91–1.28)
Hyperlipidemia present vs. absent 1.07 (0.91–1.24) 1.00 (0.85–1.19) 0.83 (0.71–0.98)
Diabetes present vs. absent 1.57 (1.30–1.89) 1.47 (1.21–1.78) 1.37 (1.13–1.66)
Family history present vs. absent 0.84 (0.70–1.01) 0.83 (0.69–1.00) 0.83 (0.69–1.00)
Smoking present vs. absent 1.05 (0.87–1.26) 1.09 (0.90–1.32) 1.04 (0.86–1.25)
Number of stenotic lesions,
per lesion increase 1.11 (1.08–1.14) Not included in the model Not included in the model
Number of stenotic vessels Not included in the model
No vessels stenosed 1.00 1.00
1 vessel stenosed 3.09 (2.38–4.01) 3.14 (2.33–4.23)
2 vessels stenosed 2.92 (2.20–3.87) 3.34 (2.44–4.57)
3 vessels stenosed 4.37 (3.35–5.69) 5.29 (3.93–7.10)
Type of treatment Not included in the model
Medical therapy only 1.00 1.00
PCI 1.74 (1.49–2.04) 1.15 (0.96–1.88)
CABG 0.74 (0.56–0.97) 0.41 (0.30–0.54)
CABG (after failed PCI) 0.21 (0.03–1.13) 0.14 (0.02–0.99)
Fig. 1. Association of glomerular filtration
rate (GFR) quartiles with death/myocardial
infarction (MI). Lines denote the following
GFR quartiles: (thick dark gray line) GFR
86; (thin line) GFR 72 to 86; (thick light
gray line) GFR 57 to 72; (thick black line)
GFR 57.
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Fig. 2. Association of GFR quartiles with
death. Lines denote the following GFR quar-
tiles: (thick dark gray line) GFR 86; (thin
line) GFR 72 to 87; (thick light gray line) GFR
57 to 72; (thick black line) GFR 57.
Fig. 3. Association of GFR quartiles with
myocardial infarction (MI). Lines denote the
following GFR quartiles: (thick dark gray line)
GFR 86; (thin line) GFR 72 to 86; (thick
light gray line) GFR 57 to 72; (thick black
line) GFR 57.
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quartile had 2.1-fold higher risk of death/MI, 42% higher in the HOPE trial was 17.8% with an annual incidence
of 3.5%. These data in a population that is consideredrisk of MI and 2.8-fold higher risk of death (Tables 1–3).
This effect persisted with statistically significant 2.1-fold to be at high cardiovascular risk are still substantially
lower than the rates of cardiovascular events and deathhigher risk of death/MI, 51% higher risk of MI and 2.6-
fold higher risk of death in multivariable models con- in the dialysis patients. Thus, it is likely that renal failure
with its associated metabolic complications greatly en-trolled for clinical variables, angiographic data and ther-
apy (Tables 1–3). hances the risks of the cardiovascular events.
There are far less data on CVD in non-dialysis chronicIn multivariable models with clinical, angiographic and
therapy variables, each 10 mL/min increase in GFR was renal failure patients. Despite the general perception
of higher CVD burden in the non-dialysis renal failureassociated with 24% decreased risk of death (HR 0.76,
95% CI 0.75 to 0.78), 8% decreased risk of MI (HR 0.92, patients, the relationship between progressive renal fail-
ure and the incidence, severity and mortality of CVD is95% CI 0.89 to 0.95) and 18% decreased risk of death/MI
(HR 0.82, 95% CI 0.80 to 0.83). unclear. There are several limitations to most of the
published studies; they were cross-sectional, used smallOf the other variables examined, age, hypertension
and diabetes increased the risk of MI in univariable mod- sample sizes and used all-cause death alone as the pri-
mary outcome. Even though death is the ultimate hardels. Male gender was associated with increased risk of
MI in multivariable model not adjusted for angiographic outcome, it would be important to understand whether
uremia per se represents an atherogenic milieu and in-and treatment variables. Due to colinearity, these effects
of age, gender and hypertension were lost in multivari- creases the risk for atherosclerotic events such as MI, in
order to design preventive strategies. Some investigatorsable models adjusted for angiographic and treatment
variables. Smoking was not independently associated have used surrogate markers for atherosclerotic disease,
such as carotid intimal media thickening in cross sec-with MI, while a familial history of coronary disease and
hyperlipidemia conferred a lower risk of MI. tional analyses [21]. In a recent cross-sectional study,
24% of patients with creatinine clearance of 50 to 75As expected, angiographic evidence of the number of
mL/min and 45% of patients with creatinine clearancestenosed vessels was a strong independent predictor of
of25 mL/min had atherosclerotic vascular disease [22].myocardial infarction and death (Tables 1–3). Percuta-
Jungers et al reported that, compared to the generalneous coronary interventions and bypass surgery were
population, patients with chronic renal failure had three-associated with lower risk of death/ MI compared to
fold higher risk of MI and stroke, but this conclusionmedical therapy (Table 1). Percutaneous coronary inter-
was based on a small study of 147 predialysis patientsventions were associated with lower risk of death but
and did not adjust for other risk factors [23]. Patientsnot MI compared to medical therapy (Tables 2 and 3)
with serum creatinine 1.7 mg/dL in the Hypertension,while CABG conferred a protective effect for both death
Detection and Follow-up Program Study also showed anand MI (Tables 2 and 3).
increase in mortality [24]. In the Cardiovascular Health
Study, increased serum creatinine was an independent
DISCUSSION predictor of mortality among 20 other different variables
The United States Renal Data Service (USRDS) re- [18].
port of a five-year survival of patients on dialysis of The reasons for the high cardiovascular mortality in
35% [17] is in sharp contrast to the five-year survival patients with renal failure remain unknown [2]. Pre-exist-
of 88% in the Cardiovascular Health Study in the general ing subclinical coronary disease could potentially ac-
population [18]. The annual mortality on dialysis in 1998 count for the observed increased CVD mortality in pa-
was 22.9%, of which 45% were due to CVD [1]. Data from tients with renal failure. In the present study, accounting
the Heart Outcomes Prevention Evaluation (HOPE) for baseline evidence of coronary disease and clinical
trial provide additional insight and perhaps indirect clues and treatment variables, the baseline GFR was indepen-
to the reasons for the high cardiovascular events in pa- dently associated with not only subsequent death, but
tients with renal failure [19]. The HOPE trial included also with MI. The ambiguity of whether subclinical, un-
patients at high risk of cardiovascular death. The mean measured underlying coronary disease is the cause of
age of 66 years and an incidence of diabetes of 39% in increased cardiovascular morbidity and mortality in pa-
that trial were comparable to the U.S. end-stage renal tients with renal failure is eliminated by the use of angi-
disease (ESRD) population [20]. A major difference be- ography, the classical gold standard for coronary disease.
tween the HOPE study subjects and the USRDS popula- Thus, these data strongly suggest that, independent of
tion is that subjects with advanced renal failure were traditional atherosclerotic risk factors, baseline angio-
excluded in the former. The cumulative incidence of MI, graphic evidence of coronary disease and therapy vari-
stroke and death over a five-year period in the placebo ables, renal failure per se increases the risk of MI and
death. It should be noted that the mean GFR in thegroup (not on angiotensin converting enzyme inhibitors)
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lowest quartile was 41 mL/min; therefore, even moderate nephropathy, only patients at very high likelihood for
renal insufficiency is associated with increased athero- severe CAD would have undergone coronary angiogra-
sclerotic risks. The association of lower GFR with death phy in the setting of renal failure. This bias could poten-
was stronger than that of the association with MI. Thus, tially induce a spuriously high association between coro-
the increased risk of death associated with renal failure nary disease and renal failure. This might be true if the
might be the result of sudden death due to ischemia or primary outcome of the study were the evidence of se-
arrhythmia, congestive heart failure and other causes in vere coronary disease at angiography. However, as the
addition to MI. Nonetheless, the 51% higher risk of study examined the risk for subsequent MI adjusted for
MI in patients in the lowest GFR quartile is clinically baseline angiographic findings, the association of MI and
significant as even a 25% higher event rate is considered renal failure is unlikely to be spurious.
significant in power calculations for interventional trials. Third, smoking and hyperlipidemia were not associ-
The potential pathogenic mechanisms for this observa- ated with MI in the present study. Further, patients with
tion could be related to elevated serum calcium  phos- familial history of coronary disease had lower risk for
phorous product [25], hyperparathyroidism [26], anemia, death/MI. This apparent paradox might have been the
hyperhomocysteinemia [8, 23, 27, 28] and chronic in- result of better life style modification and use of cardio-
flammation [21, 29–33]. These are likely intermediate protective medications in patients with these risk factors.
and not confounding variables through which uremia Finally, the limitations of the study include those of
might be associated with increased risk of MI and death. any observational analysis in a single center.
Future studies are needed to examine the relative role We conclude that even moderate renal failure, inde-
of each of these factors in uremia-induced increased risk pendent of underlying severity of coronary disease, the
of death and MI. Exclusion of these variables does not choice of therapy for coronary disease and other clinical
detract from the main conclusion of the present study characteristics, is associated with increased risk of subse-
that uremia is associated with increased risk of MI and quent MI and death. Hence, renal failure should be con-
death. sidered an additional risk factor for MI and death in
When GFR was treated as a continuous variable, each cardiovascular risk stratification strategies. These data
10 mL/min increase in GFR was associated with lower support the hypothesis that uremia per se is an athero-
risk of death/MI, death and MI. However, as Tables 1 genic milieu. The relative role of inflammation, oxidative
to 3 show, the association of lower GFR with increased and carbonyl stress, hyperhomocysteinemia, increased
risk of death and MI was not linear. There appears to serum calcium-phosphorous product, anemia, and hy-
be a biologically plausible threshold effect in this rela-
perparathyroidism in the atherogenic effects of uremia
tionship. For example, anemia, elevated serum calcium-
needs to be further delineated, in order to develop effec-phosphorous product and hyperparathyroidism are usu-
tive targeted strategies to improve cardiovascular out-ally not evident at very mildly depressed GFR levels (for
comes in renal failure.example, 90% of normal) and manifest themselves only
with more advanced renal insufficiency. Thus, use of
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